Bortezomib in the Treatment of Multiple Myeloma

  • Irene M. Ghobrial
  • Paul G. Richardson
  • Kenneth C. Anderson

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Teru Hideshima, Paul G. Richardson, Kenneth C. Anderson
    Pages 29-42
  3. Michal T. Krauze, G. David Roodman
    Pages 43-52
  4. Jesús F. San Miguel, María -Victoria Mateos
    Pages 53-68
  5. Jatin J. Shah, Robert Z. Orlowski
    Pages 79-94
  6. Andre Goy
    Pages 107-121
  7. Irene M. Ghobrial, Aldo M. Roccaro, Xavier Leleu
    Pages 123-133
  8. Morie A. Gertz, Raymond Comenzo
    Pages 135-148
  9. Dixie-Lee Esseltine, Larry Dick, Erik Kupperman, Mark Williamson, Kenneth C. Anderson
    Pages 149-176
  10. Back Matter
    Pages 177-179

About this book


Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.


Bortezomib Cancer therapy Multiple Myeloma Oncology Pharmacology Proteasome inhibitors Velcade

Editors and affiliations

  • Irene M. Ghobrial
    • 1
  • Paul G. Richardson
    • 2
  • Kenneth C. Anderson
    • 3
  1. 1.Dana-Farber Cancer Institute, Dept. Medical OncologyHarvard Medical SchoolBostonUSA
  2. 2.Dana-Farber Cancer Institute, Dept. Medical OncologyHarvard Medical SchoolBostonUSA
  3. 3.Dana-Farber Cancer Institute, Dept. Medical OncologyHarvard Medical SchoolBostonUSA

Bibliographic information